Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
- 1 January 2010
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 46 (1), 9-20
- https://doi.org/10.1016/j.ejca.2009.10.021
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repairNature Genetics, 2007
- Targeting DNA repair as a promising approach in cancer therapyEuropean Journal Of Cancer, 2007
- PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathwaysNucleic Acids Research, 2006
- Basal-like breast cancer and the BRCA1 phenotypeOncogene, 2006
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI Journal of the National Cancer Institute, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003